{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"12.8","value":"8.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"}],"units":"Participants"}],"description":"PFS was defined as the time interval between the date of the first treatment and the date of PD or death from any cause, whichever occurred first. PD: \\>/=20% relative increase and \\>/=5 mm of absolute increase in the SoD, taking as reference the smallest SoD recorded since treatment started; 1 or more new lesion(s); and/or unequivocal progression of non-target lesions. PFS was estimated by Kaplan-Meier method and 95% CI was assessed using the method of Brookmeyer and Crowley. Participants who neither progressed nor died at the time of assessment or who were lost to follow-up were censored at the date of the last tumor assessment. Participants with no post-baseline assessments were censored at the date of first dose.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received alectinib at a dose of 600 mg via capsule, orally, twice daily, continuously starting on Day 1 Cycle 1 (in 28-day cycles) until PD, death, or withdrawal for any other reasons, whichever occurred first. After PD, participants were allowed to continue treatment with alectinib as per the discretion of the treating physician.","id":"OG000","title":"Alectinib"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on safety population.","reportingStatus":"POSTED","timeFrame":"Baseline; assessments every 8 weeks post-baseline until progressive disease, unacceptable toxicity, consent withdrawal, death, other reason deemed by investigator, or last tumor assessment (up to approximately 2.5 years)","title":"Progression Free Survival (PFS) as Assessed by IRC in Safety Population","type":"SECONDARY","unitOfMeasure":"months"}